Optimizing Survival and Clinical Outcomes in Metastatic CSCC

Optimizing Survival and Clinical Outcomes in Metastatic CSCC

What Do Landmark Trials Teach Us About the Efficacy and Safety of PD?1 Targeting Immunotherapy in CSCC? Which Patients? When? For How Long? With What Results? ?From Trial?Based Data to the Front Lines of Clinical Care in Patients with Advanced Skin Cancer


Published

December 26, 2018

Created by

CMEducation Resources symposium

Related Presenters

Daniel Friedmann, MD, FAAD

Daniel Friedmann, MD, FAAD

Clinicl Research Director, Westlake Dermatology Clinical Research Center
Associate, Westlake Dermatology & Cosmetic Surgery, Austin, TX